Skip to main content
Humacyte, Inc. logo

Humacyte, Inc. — Investor Relations & Filings

Ticker · HUMA ISIN · US0207512023 US Manufacturing
Open in API
Filings indexed 463 across all filing types
Latest filing 2026-06-11 Share Issue/Capital Cha…
Country US United States of America
Listing US HUMA

About Humacyte, Inc.

https://humacyte.com/

Humacyte, Inc. is a regenerative medicine company that develops and manufactures universally implantable, bioengineered human tissues. The company utilizes a proprietary platform to produce acellular tissues that are designed to be available "off-the-shelf." Upon implantation, these tissues are repopulated by the patient's own cells, remodeling over time to become living tissue. Its first U.S. FDA-approved product, SYMVESS™, is a human acellular vessel (HAV) developed for arterial replacement and repair, particularly in cases of vascular trauma. Humacyte is leveraging its foundational technology to build a pipeline of product candidates for a broad range of diseases, injuries, and chronic conditions.

Recent filings

Filing Released Lang Actions
FORM 8-K
Share Issue/Capital Change Classification · 92% confidence The document is an SEC Form 8-K current report, with Item 1.01 disclosing an underwriting agreement for the issuance and sale of 47.6 million shares of common stock (plus an overallotment option). It constitutes an announcement of a new share issue (capital change). Under the classification definitions, this best fits “Share Issue/Capital Change” (Code: SHA), which covers announcements regarding new share issues and other capital changes.
2026-06-11 English
424B5
Share Issue/Capital Change Classification · 80% confidence The document is a prospectus supplement filed under Rule 424(b)(5) describing an offering of 47,619,048 shares of common stock, including terms of the offering, underwriting discounts, and use of proceeds. It is clearly related to a new share issuance and capital raise. It is not a full annual or interim report, nor a proxy statement. Therefore it best fits the Share Issue/Capital Change category (SHA).
2026-06-11 English
424B5
Share Issue/Capital Change Classification · 85% confidence The document is a combined prospectus supplement and accompanying base prospectus filed on Form S-3, detailing an offering of common stock (number of shares, pricing, use of proceeds, underwriting, etc.). This is the primary disclosure document for a new equity issuance and shelf registration. It is not an earnings release, proxy statement, or management discussion, nor is it a request for shareholder votes or a routine regulatory notice. It constitutes the formal offering documentation for a share issue. Therefore it falls under the category for announcements relating to new share issues and capital changes (SHA).
2026-06-10 English
FORM 8-K
Regulatory Filings Classification · 85% confidence The document is a U.S. SEC Form 8-K “Current Report” announcing other events, a press release, and an investor presentation as exhibits. It does not contain full financial statements or serve as a dedicated investor presentation file, but is a regulatory announcement filed under the Securities Exchange Act. Therefore, it falls under general regulatory filings (RNS).
2026-06-10 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is a U.S. SEC Form 8-K “Current Report” filed by Humacyte, Inc. reporting two principal items from its Annual Meeting of Stockholders on June 9, 2026: an amendment to its certificate of incorporation (increasing authorized common shares) and, critically, the detailed tabulation of shareholder votes on five proposals. Given our filing definitions, this is an announcement of official shareholder voting results. Therefore it best fits Declaration of Voting Results & Voting Rights Announcements (DVA) rather than a general regulatory filing or other category.
2026-06-09 English
FORM 8-K
Regulatory Filings Classification · 82% confidence The document is a U.S. SEC Form 8-K “Current Report” filed by Humacyte, Inc. reporting notification from Nasdaq that the company has regained compliance with the minimum bid price requirement. There is no presentation of financial statements, no earnings release, no board or management changes, and no AGM materials. It is a regulatory disclosure of an event, so it falls under the general “Regulatory Filings” category (RNS).
2026-06-05 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.